Interaction of Common Azole Antifungals with P Glycoprotein

Er-jia Wang, Karen Lew, Christopher N. Casciano, Robert P. Clement, and William W. Johnson*

Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Lafayette, New Jersey 07848

Received 13 June 2001/Returned for modification 8 August 2001/Accepted 1 October 2001

Both eucaryotic and procaryotic cells are resistant to a large number of antibiotics because of the activities of export transporters. The most studied transporter in the mammalian ATP-binding cassette transporter superfamily, P glycoprotein (P-gp), ejects many structurally unrelated amphiphilic and lipophilic xenobiotics. Observed clinical interactions and some in vitro studies suggest that azole antifungals may interact with P-gp. Such an interaction could both affect the disposition and exposure to azole antifungal therapies and partially explain the clinical drug interactions observed with some antifungals. Using a whole-cell assay in which the retention of a marker substrate is evaluated and quantified, we studied the abilities of the most widely prescribed orally administered azole antifungals to inhibit the function of this transporter. In a cell line presenting an overexpressed amount of the human P-gp transporter, itraconazole and ketoconazole inhibited P-gp function with 50% inhibitory concentrations (IC50s) of ~2 and ~6 µM, respectively. Cyclosporin A was inhibitory with an IC50 of 1.4 µM in this system. Uniquely, fluconazole had no effect in this assay, a result consistent with known clinical interactions. The effects of these azole antifungals on ATP consumption by P-gp (representing transport activity) were also assessed, and the Km values were congruent with the IC50s. Therefore, exposure of tissue to the azole antifungals may be modulated by human P-gp, and the clinical interactions of azole antifungals with other drugs may be due, in part, to inhibition of P-gp transport.

Although the cell membrane is an efficient barrier to hydrophilic molecules, many amphiphilic compounds diffuse through the domains of the bilayer. Therefore, active mechanisms exist to protect cells from intrusion from amphiphilic molecules, some of which may possess potentially harmful biological qualities. The active efflux of a wide spectrum of xenobiotics from procaryotic as well as eucaryotic cells confers resistance to a large number of antibiotics and is known as multidrug resistance (MDR) (24). Active MDR is largely conferred by ATP-binding cassette (ABC) transporters, which can contribute significantly to drug disposition and resistance to therapy, as well as to acquired bacterial and mammalian resistance. These transporters recognize a broad variety of xenobiotics, including drugs. Of the various forms of mammalian ABC transporters, P-glycoprotein (P-gp) has received the most attention, as it plays a major role in the disposition of many drugs and is the most ubiquitous (9–12). The product of the MDR1 gene, P-gp, is an ~170-kDa phosphorylated glycoprotein. Other members of this family include the MDR proteins (MRP1, MRP2, MRP3, etc.).

These transport proteins are ATP-driven pumps that remove xenobiotics from the interiors of mammalian cells. Expression of P-gp in normal human tissues—particularly within the cellular membranes of the gastrointestinal tract, liver, blood-brain barrier, adrenals, and kidneys—suggests that the enzyme plays a role in cellular protection as well as in secretion and/or disposition (10). While the primary function of this protein is unknown, its ability to confer resistance to a wide variety of structurally and chemically unrelated compounds remains impressive. Indeed, the list of substrates that this transporter tolerates or accepts now appears to be similar to that for cytochrome P450 3A4 (CYP3A4), the predominant intestinal and hepatic cytochrome P450 oxygenase, and may even prove to recognize more substrates.

As a member of the ABC superfamily of transporters, P-gp possesses two ATP binding sites and uses ATP (via hydrolysis) as the source of energy for the “translocation” of substrates. The substrates enter from the lipid bilayer (27) and can bind to two (or more) nonidentical sites (35). Moreover, allosteric and perhaps synergistic effects have been observed for certain substrate combinations and conditions (36).

Although drug interactions mediated by P-gp are difficult to distinguish from those mediated by CYP3A4, coadministration of azole antifungals with other CYP3A4 and/or P-gp substrates is known to cause many clinical effects (32). Lovastatin monotherapy has an ~0.1% risk of causing skeletal muscle toxicity that dramatically increases when lovastatin (a P-gp substrate) (37) is combined with drugs such as cyclosporine, itraconazole, ketoconazole, or erythromycin (14). In vitro studies suggest that ketoconazole is an inhibitor of P-gp on the basis of the reversal of resistance and enhanced retention of marker substrates in a multidrug-resistant cell line (29). The transport of some compounds by kidney and intestinal cell monolayers has been affected by ketoconazole (17, 38), which competed with verapamil binding to Caco-2 cells with a 50% inhibitory concentration (IC50) of 13 µM (5). However, ketoconazole inhibited polarized transport of the P-gp/CYP3A4 substrate K02 in MDRI-MDCK cells with an IC50 of 119 µM (40), and 100 µM ketoconazole only weakly inhibited rhodamine 123 (Rho) transport across a Caco-2 cell monolayer and everted rat ileum (39).

Itraconazole is suggested to be a P-gp substrate because of increased brain accumulation in mdrla−/− mice deficient in
P-gp (21). Itraconazole can also reverse resistance to the P-gp substrate daunorubicin (DNR) in a murine acute leukemia cell line in vitro (multidrug-resistant cells) (13), while the methylthiazolyl diphenyltetrazolium bromide (MTT) cytotoxicity assay results suggest an interaction of itraconazole with MDR and/or multidrug resistance protein (MRP)-associated resistance because of resistance reversal (18). The transport of vinblastine, DNR, and doxorubicin is affected by 100 μM itraconazole in cells transfected with MDR1 cDNA (31). Furthermore, clinical interactions have been reported following coadministration of itraconazole with vincristine (2), DNR (13, 33), quinidine (16), or digoxin (15), all of which, as it has been asserted, are P-gp substrates (with the first three being well characterized). Lovastatin concentrations increased more than 20-fold when it was coadministered with itraconazole (22). The oral bioavailability of simvastatin is also significantly increased by treatment with itraconazole or cyclosporine (3, 19, 23, 25).

In contrast to the effects caused by ketoconazole and itraconazole, fluconazole did not inhibit the transport of digoxin across MDCK cell monolayers (38).

The objective of the present study was to quantify the interactions of these commonly prescribed azole antifungals with the MDR1 ABC transporter P-gp. Using two different methods of assessment, we show herein the distinct interaction by all antifungals except fluconazole.

**MATERIALS AND METHODS**

**Chemicals.** Itraconazole was obtained from Schering-Plough compound sources. Ketoconazole, DNR, verapamil, colchicine, cyclosporine A, mannitol, dithiothreitol, ATP disodium, ammonium molybdate, ascorbic acid, sodium metasulfonate, aprotinin, leupeptin, EGTA, EDTA, HEPES, ouabain, phenylmethylsulfonyl fluoride, and TRIZMA base were purchased from Sigma Chemical Co. (St. Louis, Mo.). Fluconazole was purchased from ICN Pharmaceuticals (Costa Mesa, Calif.). Hanks’ balanced salt solution, alpha minimum essential medium, Dulbecco’s modified minimal essential medium, penicillin-streptomycin, fetal bovine serum, and trypsin-EDTA were obtained from Life Technologies, Inc. (Rockville, Md.). Sodium orthovanadate was purchased from Fluka and Bauer Inc. (Waterbury, Conn.). Microplates (96-well; Fisher), plastic tubes, and cell culture flasks (75 cm²) were purchased from Corning Inc. (Corning, N.Y.). All other reagents were of the highest grade commercially available.

**Cell lines.** The CR1R12 cell line, provided by Alan Senior (University of Rochester), was maintained in complete alpha minimum essential medium supplemented with 10% fetal bovine serum and penicillin-streptomycin (50 U and 50 μg/ml, respectively) in a 5% CO₂–95% air atmosphere at 37°C. Colchicine (0.5 μg/ml) was added to the culture medium. The NIH-3T3-G185 cell line, which expresses the gene product of human MDR1, was licensed from the National Institutes of Health (NIH) and maintained in Dulbecco’s modified minimal essential medium. Colchicine (60 ng/ml) was added to the culture medium. The NIH-3T3-G185 cell line (which expresses the gene product of human MDR1) was frozen and were stored at −80°C until analysis. Protein content was determined by a microassay adaptation of the Lowry method (37).

**ATP hydrolysis and phosphate release.** The consumption of ATP was quantified by determining the amount of inorganic orthophosphate, which forms a color complex with molybdate, that was liberated (4, 35). We have modified an ATP hydrolysis assay, based on determination of the amount of phosphate released, using membrane microsomal preparations; the assay was carried out in a 96-well microplate (35). The microsomes were thawed on ice prior to dilution to 3.5 μg of protein per well in ice-cold ATPase buffer (3 mM sodium ATP, 50 mM KCl, 10 mM MgSO₄, 3 mM dithiothreitol, 50 mM Tris-HCl [pH 7.0]) containing 0.5 μg/EDTA (to inhibit Ca-ATPase), 0.5 μM ouabain (to inhibit the Na- and K-ATPases), and 3 mM sodium azide (to inhibit the mitochondrial ATPase). The total incubation volume including the various inhibitors was 100 μl. The incubation reaction was initiated by transferring the plate from ice to 37°C; the plate was incubated for 30 min, and then the reaction was terminated by the addition of 50 μl of a 12% sodium dodecyl sulfate solution at room temperature, followed by the addition of 50 μl of a mixture (in equal volumes) of 18% fresh ascorbic acid in 1 N HCl and 3% ammonium molybdate in 1 N HCl. After 4 min, 100 μl of a solution of 2% sodium citrate and 2% sodium metasulfonate in 2% acetic acid was added to fix the color formation. After 30 min of incubation at room temperature, the fixed and released phosphate was quantified colorimetrically with a microplate reader (FL9600; Bio-Tek, Winooski, Vt.) at 750 nm. By comparison to a standard curve, the amount of phosphate released—and hence, the amount of ATP consumed—was quantified. Water-insoluble drugs were dissolved in methanol or dimethyl sulfoxide; the maximum methanol or dimethyl sulfoxide concentration (2% [vol/vol]) was shown not to affect the ATPase activity.

**RESULTS**

As fluorescent substrates transported by mammalian P-gp, DNR and Rho serve as markers for active transport function simply by measurement of the amount of fluorescence retained per cell (34). Herein we show that some azole antifungals can effectively inhibit the P-gp-mediated transport of DNR or Rho.

The IC₅₀ can be determined from a simple function, as shown in Fig. 1, which shows the retained fluorescence for samples of viable cells measured with a flow cytometer at various concentrations of the antifungal. The concentration dependency of inhibition displayed a sigmoidal response curve (Fig. 1; see Fig. 2), a consequence of cooperativity (36), with the Hill equation. The concentration dependency of inhibition displayed a sigmoidal response curve (Fig. 1; see Fig. 2), a consequence of cooperativity (36), with the Hill equation.
was about 1.7 μM, and itraconazole could achieve about 16% of the maximal inhibition achieved with the reference standard (vanadate). An inhibition extent of about 30% of the maximal (reference) inhibition can be achieved for many known P-gp substrates and inhibitors (34). Cyclosporin A inhibited this process with an IC₅₀ of about 1.4 μM. For example, the inhibition of DNR transport observed for the commonly used positive control P-gp inhibitor verapamil represented 40% of the complete inhibition observed for vanadate in the same experiment. As shown in Fig. 1B, itraconazole had no significant effect on the transport of Rho (another fluorescent marker). This result is likely due to the distinct binding sites on P-gp that have often been described (35, 36). Because these cell lines overexpress the respective transporter enzymes, the IC₅₀ would be expected to be higher in these evaluations than under in vivo conditions, where far fewer copies of the enzyme would be contained per cell. Ketoconazole exhibited effects similar to those of itraconazole (ketoconazole IC₅₀ ~6 μM), as shown in Fig. 2 and summarized in Table 1. Fluconazole, however, appeared to have no effect on the active efflux of DNR or Rho from this cell line and would therefore not be expected to be a significant inhibitor of the function of P-gp (Fig. 3).

**ATP hydrolysis.** As ATP is consumed at a purported rate of about one or two molecules per transport event, the hydrolysis

---

**TABLE 1. Inhibition parameters of P-gp-mediated transport of DNR or Rho in rodent multidrug-resistant cell line or cell line transfected with human MDR1**

<table>
<thead>
<tr>
<th>Antifungal</th>
<th>Marker</th>
<th>IC₅₀ (μM)</th>
<th>Iₘₜₐₓ (%)</th>
<th>n (Hill coefficient)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Itraconazole</td>
<td>DNR</td>
<td>1.7 ± 0.2</td>
<td>16 ± 0.3</td>
<td>1.9 ± 0.4</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Rho</td>
<td>NE</td>
<td>NE</td>
<td>NA</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>DNR</td>
<td>5.6 ± 0.4</td>
<td>40 ± 1</td>
<td>1.6 ± 0.2</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Rho</td>
<td>49 ± 3.4</td>
<td>51 ± 2</td>
<td>2.9 ± 0.5</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>DNR</td>
<td>NE</td>
<td>NE</td>
<td>NA</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>Rho</td>
<td>NE</td>
<td>NE</td>
<td>NA</td>
</tr>
</tbody>
</table>

* Data are nonlinear regression solutions to the Hill function followed by the standard error.
* Iₘₜₐₓ, percentage of the complete inactivation that occurred with vanadate. Verapamil inhibited DNR transport 40% compared with the inactivation by vanadate.
* NE, no effect on function.
* NA, not available.
of ATP represents the transport activity or the transport function (1, 6, 28, 30, 35). Itraconazole caused a concentration-dependent increase in the rate of ATP hydrolysis relative to the baseline rate, indicating that as a substrate for P-gp it causes comparatively rapid hydrolysis (Fig. 4A). The $K_m$ was $0.8 \pm 0.2 \text{ M}$, and the $V_{\text{max}}$ was about twofold above the baseline $V_{\text{max}}$, as indicated in Table 2. The presence of itraconazole with the membrane fraction from the parent cell line (CHO) resulted in no significant changes in ATP hydrolysis, thus serving as a negative control. Similarly, ketoconazole exhibited a $K_m$ of $8.6 \pm 3.2 \text{ M}$ and a $V_{\text{max}}$ of about five times the baseline $V_{\text{max}}$ (Fig. 4B and Table 2). Fluconazole appeared to be a substrate of medium efficiency for the P-gp transporter, as there was a change in the turnover rate, and the data suggested a $K_m$ of $2.5 \pm 0.8 \text{ M}$ (with large confidence limits due to error) and a $V_{\text{max}}$ of about twofold above the baseline $V_{\text{max}}$ (Table 2). The results of the assay of ATP hydrolysis activity were consonant with those of the assays of transport function inhibition (described above), with the possible exception of the results for fluconazole.

**DISCUSSION**

Azole antifungals are widely prescribed for chemoprophylaxis (20). Our results demonstrate the inhibition of the human P-gp-mediated ATP hydrolysis activity at clinically relevant concentrations of itraconazole, ketoconazole, and fluconazole. The data were fit to a hyperbola. For itraconazole, $V_{\text{max}}$ was equal to $69 \pm 1.5 \text{ nmol/min/mg}$ of membrane protein, with $K_m$ equal to $0.8 \pm 0.2 \text{ M}$. For ketoconazole, $V_{\text{max}}$ was equal to $53 \pm 7 \text{ nmol/min/mg}$ membrane protein, with $K_m$ equal to $8.6 \pm 3 \text{ M}$. For fluconazole, $V_{\text{max}}$ was equal to $61 \pm 2.3 \text{ nmol/min/mg}$ membrane protein, with $K_m$ equal to $2.5 \pm 1 \text{ M}$. $V_0$, initial velocity.
P-gp transport function by some azole antifungals. The observed inhibition was concentration dependent, with IC₅₀ₐₙ of <2 mM for itraconazole and ~5 mM for ketoconazole when DNR was used as the marker substrate. Cyclosporin A was inhibitory with an IC₅₀ of 1.4 µM in this system. These experiments used the NIH-3T3-G185 cell line, which expresses larger than normal quantities of the human P-gp transporter. Because these cell lines overexpress the transporter enzyme, the IC₅₀ would be expected in these evaluations to be higher than those encountered under in vivo conditions, where far fewer copies of the enzyme would be contained per cell. ATP hydrolysis kinetics showed that itraconazole interacts with P-gp with a half-maximal saturation concentration of ~1 µM. Since itraconazole, ketoconazole, and fluconazole are known to bind to CYP3A4 (although fluconazole binds only weakly) and since the substrate definitions for both CYP3A4 and P-gp are similar (diverse lipophilic structures with molecular weights of ~300 to 1,000) and, hence, share most substrates, it is not surprising that these azole antifungals would also bind to the substrate binding site of P-gp. Indeed, the structures typify the type II unit of three electron donor groups with a spatial separation of 4.6 ± 0.6 Å suggested by Seelig (26) as one of two general patterns for substrate recognition by P-gp (constructed from a structure-activity relationship study of known substrates of P-gp).

Clinical observations seem to indicate that theazole antifungals interact with the P-gp transporter. The concentrations of lovastatin, a P-gp substrate and inhibitor (37), in plasma increased more than 20-fold when it was coadministered with itraconazole (22). Furthermore, the oral bioavailability of simvastatin was also significantly increased by treatment with itraconazole or cyclosporine A (3, 19, 23, 25). Since itraconazole and cyclosporine A are both inhibitors of P-gp and CYP3A4, it is difficult to discern the dominant avenue of interaction.

In contrast to itraconazole and ketoconazole, fluconazole did not appear to inhibit the active transport of the marker substrates DNR and Rhö by P-gp. Fluconazole may be a substrate for active transport by P-gp, with very slow passive diffusion across the membrane, thus impeding reentry and interaction with the substrate binding site (7, 8). Indeed, the fluconazole molecule is significantly shorter, smaller, and more hydrophilic than the other two antifungals considered herein.

Two of theazole antifungals tested in the present study (itraconazole and ketoconazole) are further examples of effective inhibitors or substrates of both P-gp and CYP3A4. Hence, resistance to antifungal treatment can be conferred by both of these enzymes. Since P-gp has a significant effect on the absorption and disposition of orally administered drugs, its role might be as significant as that of CYP3A4. Many, if not all, of the known clinical interactions withazole antifungals are with compounds that are substrates of P-gp, which therefore may be significant in terms of the observed clinical interactions. As several of theseazole antifungals effectively inhibit the function of P-gp, clinical interactions may be expected with other high-affinity P-gp substrates.

ACKNOWLEDGMENTS

We are grateful to Adrian L. Stewart for editorial assistance and Eleanor Johnson for comments.

REFERENCES


<table>
<thead>
<tr>
<th>Antifungal</th>
<th>Km (µM)</th>
<th>Vmax (nmol/min/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Itraconazole</td>
<td>0.8 ± 0.2</td>
<td>69 ± 2</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>8.6 ± 3</td>
<td>53 ± 7</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>2.5 ± 1</td>
<td>61 ± 2</td>
</tr>
</tbody>
</table>

TABLE 2. Kinetic parameters of ATP hydrolysis in the presence ofazole antifungals